Aritech PMA
This article was originally published in The Gray Sheet
Executive Summary
Following 800-patient Protect AF clinical trial for its Watchman left atrial appendage (LAA) closure technology, company announces Aug. 18 it has filed a PMA with FDA. The LAA closure technology is designed to prevent stroke by keeping blood clots from entering the blood stream. Aritech plans to market the device as an alternative for atrial fibrillation patients who prefer not to take blood thinning medications for life. The Plymouth, Minn., firm also late year purchased left atrial appendage closure device intellectual property from ev3